Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02075021 · OUTCOME

the Number of Patients Who Achieve Complete Response (CR) or Partial Response (PR) (Phase II)

Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma · Source last updated 2018-10-15

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
up to 2 years

What was measured

The response will be determined using the International Uniform Response Criteria for Multiple Myeloma.

Analysis population: Results were not analyzed due to lack of sufficient data. PI left the institution.

Groups in this outcome

Lenalidomide and Nab-paclitaxel

100 mg/m\^2 of Abraxane weekly for 3 weeks and 10 mg Revlimid daily for 21 days, with a dose escalation for Revlimid to 15 mg and to 25 mg. One cycle is 4 weeks. Dose de-escalations will also be performed for both drugs as necessary. Patients will be treated until disease progression. Lenalidomide nab-paclitaxel

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Lenalidomide and Nab-paclitaxel0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    units
    Participants
description
The response will be determined using the International Uniform Response Criteria for Multiple Myeloma.
groups
  1. description
    100 mg/m\^2 of Abraxane weekly for 3 weeks and 10 mg Revlimid daily for 21 days, with a dose escalation for Revlimid to 15 mg and to 25 mg. One cycle is 4 weeks. Dose de-escalations will also be performed for both drugs as necessary. Patients will be treated until disease progression. Lenalidomide nab-paclitaxel
    id
    OG000
    title
    Lenalidomide and Nab-paclitaxel
population Description
Results were not analyzed due to lack of sufficient data. PI left the institution.
reporting Status
POSTED
time Frame
up to 2 years
title
the Number of Patients Who Achieve Complete Response (CR) or Partial Response (PR) (Phase II)
type
SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice